Amgen (NASDAQ:AMGN) announces plans for a long-term study, expected to enroll at least 13,000 people at high risk of a first cardiovascular (CV) event despite optimized treatment with lipid-lowering therapy, aimed at assessing the effectiveness of Repatha (evolocumab) in lowering CV risk in this population.
Enrollment in the Phase 3 trial, VESALIUS-CV, should start next quarter. The dual endpoints are: the time to coronary heart disease (CHD) death, myocardial infarction (MI), ischemic stroke (triple component) and time to CHD death, MI, ischemic stroke or any ischemia-driven arterial revascularization, whichever occurs first (quadruple component).
The estimated completion date is May 2024.
Subscribe for full text news in your inbox